Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II study designed to evaluate whether the co-administration of a fixed dose
of tesmilifene and a standard regimen of docetaxel alters the plasma pharmacokinetics of
docetaxel. This study will also assess the safety and efficacy of the tesmilifene/docetaxel
combination in metastatic breast cancer patients.